Analytical Data
-
Gene name
FFAR4
- Application
-
Alternative Names
FFAR4；GPR120；GPR129；O3FAR1；Free fatty acid receptor 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5NUL3
-
Expression Region
1-361aa
-
AA Sequence
MSPECARAAGDAPLRSLEQANRTRFPFFSDVKGDHRLVLAAVETTVLVLIFAVSLLGNVCALVLVARRRRRGATACLVLNLFCADLLFISAIPLVLAVRWTEAWLLGPVACHLLFYVMTLSGSVTILTLAAVSLERMVCIVHLQRGVRGPGRRARAVLLALIWGYSAVAALPLCVFFRVVPQRLPGADQEISICTLIWPTIPGEISWDVSFVTLNFLVPGLVIVISYSKILQITKASRKRLTVSLAYSESHQIRVSQQDFRLFRTLFLLMVSFFIMWSPIIITILLILIQNFKQDLVIWPSLFFWVVAFTFANSALNPILYNMTLCRNEWKKIFCCFWFPEKGAILTDTSVKRNDLSIISG
-
Molecular Weight
40.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FFAR4, also known as Free Fatty Acid Receptor 4 or GPR120, is a G protein-coupled receptor that has gained attention in the field of metabolic research due to its role in regulating energy homeostasis and inflammation. Initially identified for its ability to sense long-chain fatty acids, FFAR4 mediates physiological responses to dietary fats, influencing insulin secretion and adipocyte function. The receptor's activation has been linked to improved insulin sensitivity and anti-inflammatory effects, making it a promising target for treating metabolic disorders such as obesity, type 2 diabetes, and cardiovascular diseases. Research has explored the therapeutic potential of FFAR4, revealing its involvement in the modulation of gut microbiota, appetite regulation, and fat metabolism. However, the exact mechanisms by which FFAR4 exerts its beneficial effects remain unclear, necessitating further investigation into its signaling pathways and interactions with various ligands. Recent studies on recombinant FFAR4 proteins aim to better understand its structure-function relationships and develop specific agonists or antagonists that could serve as novel therapeutic agents. As obesity and related metabolic diseases continue to rise globally, FFAR4 research is positioned at the forefront of efforts to discover new treatments that could mitigate these significant health challenges.
